CA3072439A1 - Selective inhibitors of protein arginine methyltransferase 5 (prmt5) - Google Patents

Selective inhibitors of protein arginine methyltransferase 5 (prmt5) Download PDF

Info

Publication number
CA3072439A1
CA3072439A1 CA3072439A CA3072439A CA3072439A1 CA 3072439 A1 CA3072439 A1 CA 3072439A1 CA 3072439 A CA3072439 A CA 3072439A CA 3072439 A CA3072439 A CA 3072439A CA 3072439 A1 CA3072439 A1 CA 3072439A1
Authority
CA
Canada
Prior art keywords
methyl
compound
c6alk
amino
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3072439A
Other languages
English (en)
French (fr)
Inventor
Juan Luengo
Hong Lin
Rupa SHETTY
Michael Hawkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prelude Therapeutics Inc
Original Assignee
Prelude Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prelude Therapeutics Inc filed Critical Prelude Therapeutics Inc
Publication of CA3072439A1 publication Critical patent/CA3072439A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
CA3072439A 2017-08-09 2018-08-09 Selective inhibitors of protein arginine methyltransferase 5 (prmt5) Pending CA3072439A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762543141P 2017-08-09 2017-08-09
US62/543,141 2017-08-09
US201862630581P 2018-02-14 2018-02-14
US62/630,581 2018-02-14
US201862664442P 2018-04-30 2018-04-30
US62/664,442 2018-04-30
PCT/US2018/046057 WO2019032859A1 (en) 2017-08-09 2018-08-09 SELECTIVE INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5)

Publications (1)

Publication Number Publication Date
CA3072439A1 true CA3072439A1 (en) 2019-02-14

Family

ID=63405398

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3072439A Pending CA3072439A1 (en) 2017-08-09 2018-08-09 Selective inhibitors of protein arginine methyltransferase 5 (prmt5)

Country Status (18)

Country Link
US (4) US10570140B2 (enExample)
EP (2) EP3939986A1 (enExample)
JP (1) JP2020530496A (enExample)
KR (1) KR20200036922A (enExample)
CN (1) CN111527099B (enExample)
AU (1) AU2018313910B2 (enExample)
BR (1) BR112020002736A2 (enExample)
CA (1) CA3072439A1 (enExample)
DK (1) DK3665179T3 (enExample)
ES (1) ES2885180T3 (enExample)
IL (1) IL272519B (enExample)
MA (1) MA49840A (enExample)
MX (1) MX2020001598A (enExample)
PL (1) PL3665179T3 (enExample)
PT (1) PT3665179T (enExample)
UA (1) UA126481C2 (enExample)
WO (1) WO2019032859A1 (enExample)
ZA (1) ZA202000773B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020530496A (ja) * 2017-08-09 2020-10-22 プレリュード セラピューティクス，インコーポレイティド タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤
ES2963436T3 (es) * 2018-03-14 2024-03-27 Prelude Therapeutics Inc Inhibidores selectivos de la proteína arginina metiltransferasa 5 (PRMT5)
US10711007B2 (en) 2018-03-14 2020-07-14 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
EP3833669A4 (en) * 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
US12173026B2 (en) * 2018-08-07 2024-12-24 Merck Sharp & Dohme Llc PRMT5 inhibitors
AU2020223058A1 (en) * 2019-02-13 2021-09-09 Prelude Therapeutics, Incorporated Selective inhibitor of protein arginine methyltransferase 5 (PRMT5)
JP7609798B2 (ja) * 2019-03-25 2025-01-07 カリフォルニア インスティチュート オブ テクノロジー Ｐｒｍｔ５インヒビター及びその使用
EP3952874A4 (en) * 2019-04-05 2022-12-28 Prelude Therapeutics, Incorporated SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5
EP3946352A4 (en) * 2019-04-05 2022-12-28 Prelude Therapeutics, Incorporated SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5
AU2020283505A1 (en) * 2019-05-30 2021-12-23 Angex Pharmaceutical, Inc. Heterocyclic compounds as PRMT5 inhibitors
CA3154566A1 (en) * 2019-09-18 2021-03-25 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2021079196A2 (en) * 2019-10-21 2021-04-29 Accent Therapeutics, Inc Mettl3 modulators
CA3156135A1 (en) * 2019-10-22 2021-04-29 Lupin Limited PHARMACEUTICAL COMBINATION OF PRMT5 INHIBITORS
US12403137B2 (en) 2019-10-28 2025-09-02 Tango Therapeutics, Inc. Compounds and methods of use
CN116568677A (zh) 2020-07-31 2023-08-08 探戈医药股份有限公司 可用于治疗mtap缺乏和/或mta累积癌症的哌啶-1-基-n-吡啶-3-基-2-氧代乙酰胺衍生物
MX2023003264A (es) 2020-09-21 2023-06-06 Prelude Therapeutics Inc Inhibidores de cdk y su uso como productos fármaceuticos.
US20220251088A1 (en) * 2020-12-10 2022-08-11 Prelude Therapeutics, Incorporated Processes for Making PRMT5 Inhibitors
CN116888120A (zh) * 2020-12-16 2023-10-13 美国安进公司 Prmts抑制剂
MX2023007265A (es) 2020-12-18 2023-08-14 Prelude Therapeutics Inc Inhibidores de cdk y su uso como productos farmacéuticos.
WO2023001133A1 (zh) * 2021-07-20 2023-01-26 上海齐鲁制药研究中心有限公司 Prmt5抑制剂
US20230181589A1 (en) * 2021-12-03 2023-06-15 The Trustees Of Indiana University Prmt5 inhibitors for ocular therapy
US11939340B2 (en) 2022-01-21 2024-03-26 Prelude Therapeutics Incorporated CDK inhibitors and their use as pharmaceuticals
WO2023150612A1 (en) 2022-02-03 2023-08-10 Prelude Therapeutics, Incorporated Cdk inhibitors and their use as pharmaceuticals
US20240018136A1 (en) 2022-03-09 2024-01-18 Prelude Therapeutics, Incorporated CDK Inhibitors And Their Use As Pharmaceuticals
JP2025510738A (ja) 2022-03-23 2025-04-15 プレリュード・セラピューティクス・インコーポレイテッド 多型化合物及びその使用
CN116655638B (zh) * 2022-05-12 2024-01-26 上海齐鲁制药研究中心有限公司 氘代prmt5抑制剂
US20240150340A1 (en) 2022-10-06 2024-05-09 Prelude Therapeutics Incorporated CDK Inhibitors And Their Use As Pharmaceuticals
US20240352029A1 (en) 2023-04-14 2024-10-24 Prelude Therapeutics Incorporated CDK Inhibitors And Their Use As Pharmaceuticals
CN116554194A (zh) * 2023-05-23 2023-08-08 江苏八巨药业有限公司 一种卡培他滨中间体的合成方法
WO2025064402A1 (en) * 2023-09-22 2025-03-27 St. Jude Children's Research Hospital, Inc. Method for treating sickle cell disease by targeting senescent cells

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
DE102010060118A1 (de) * 2010-10-22 2012-04-26 Röhm Gmbh Stirnseitenmitnehmer
AU2011336272A1 (en) 2010-12-03 2013-06-20 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
EP2663309B1 (en) * 2011-01-10 2017-03-15 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2014100719A2 (en) * 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EP2970136A1 (en) * 2013-03-14 2016-01-20 Epizyme, Inc. Arginine methyl transferase inhibtors and uses thereof
US9856218B2 (en) * 2013-03-15 2018-01-02 Ohio State Innovation Foundation Inhibitors of PRMT5 and methods of their use
EP3160477A4 (en) * 2014-06-25 2018-07-04 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US20170210751A1 (en) * 2014-06-25 2017-07-27 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EP3212201B1 (en) 2014-10-28 2022-10-19 BCI Pharma Nucleoside kinase inhibitors
KR101719881B1 (ko) * 2014-12-22 2017-03-24 삼성전기주식회사 렌즈 모듈
EA031895B1 (ru) * 2015-02-24 2019-03-29 Пфайзер Инк. Замещенные нуклеозидные производные, полезные в качестве агентов против рака
AR104326A1 (es) * 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
TWI791251B (zh) * 2015-08-26 2023-02-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物
EP3426664B1 (en) 2016-03-10 2021-06-30 Janssen Pharmaceutica NV Substituted nucleoside analogues for use as prmt5 inhibitors
WO2017218802A1 (en) 2016-06-15 2017-12-21 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018075601A1 (en) 2016-10-18 2018-04-26 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018085833A2 (en) 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyl transferase 5 (prmt5)
WO2018085818A1 (en) 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018152548A1 (en) 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018152501A1 (en) 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
EA201990851A1 (ru) 2017-02-24 2019-09-30 Янссен Фармацевтика Нв Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
WO2018160855A1 (en) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018160824A1 (en) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
JP2020530496A (ja) 2017-08-09 2020-10-22 プレリュード セラピューティクス，インコーポレイティド タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤
US11524962B2 (en) 2017-10-26 2022-12-13 Prelude Therapeutics, Incorporated Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (PRMT5)
EP3833669A4 (en) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS

Also Published As

Publication number Publication date
ES2885180T3 (es) 2021-12-13
US20200361946A1 (en) 2020-11-19
IL272519A (en) 2020-03-31
US10570140B2 (en) 2020-02-25
ZA202000773B (en) 2022-07-27
JP2020530496A (ja) 2020-10-22
US11208416B2 (en) 2021-12-28
MA49840A (fr) 2020-06-17
US20190048014A1 (en) 2019-02-14
US11078205B2 (en) 2021-08-03
EP3665179B1 (en) 2021-06-09
AU2018313910B2 (en) 2022-12-08
WO2019032859A1 (en) 2019-02-14
UA126481C2 (uk) 2022-10-12
DK3665179T3 (da) 2021-08-16
EP3665179A1 (en) 2020-06-17
PL3665179T3 (pl) 2021-11-29
US20200148692A1 (en) 2020-05-14
CN111527099A (zh) 2020-08-11
KR20200036922A (ko) 2020-04-07
MX2020001598A (es) 2020-10-28
US20220153747A1 (en) 2022-05-19
IL272519B (en) 2022-05-01
AU2018313910A1 (en) 2020-03-05
BR112020002736A2 (pt) 2020-07-28
PT3665179T (pt) 2021-09-10
CN111527099B (zh) 2024-03-22
EP3939986A1 (en) 2022-01-19

Similar Documents

Publication Publication Date Title
US11208416B2 (en) Selective inhibitors of protein arginine methytransterase 5 (PRMT5)
US20230174539A1 (en) Substituted Pyrrolo[2,3-D]Pyrimidines As Inhibitors Of Protein Arginine Methyl Transferase 5 (PRMT5)
KR102803162B1 (ko) 단백질 아르기닌 메틸트랜스퍼라제 5(prmt5)의 선택적 억제제
WO2018160824A1 (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
US12414953B2 (en) Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
HK40067540A (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
HK40031042B (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
HK40031042A (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
EA040066B1 (ru) Селективные ингибиторы протеин-аргинин-метилтрансферазы 5 (prmt5)
HK40043601B (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
HK40043601A (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230801

EEER Examination request

Effective date: 20230801